Generic Name: dolutegravir + abacavir + lamivudine
Drug Class: Single-Tablet Regimens
Company: ViiV Healthcare
Approval Status: Approved
Generic Version Available: No
A treatment regimen recommended for previously untreated people living with HIV, as indicated by the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.
Triumeq is a single-tablet regimen for HIV. It contains three different types of HIV drugs: one integrase inhibitor and two nucleoside reverse transcriptase inhibitors. Triumeq was approved by the U.S. Food and Drug Administration for use by people living with HIV in August 2014.
Triumeq is a combination of three drugs: Tivicay (dolutegravir), Ziagen (abacavir) and Epivir (lamivudine). All three drugs can be purchased individually for use in combination with other HIV drugs.
Triumeq is considered to be a complete one-pill, once-daily HIV treatment regimen for HIV-positive people whose virus is fully sensitive to integrase inhibitors, abacavir and lamivudine.
Adult Dose: One tablet once a day. Each tablet contains 50 mg dolutegravir, 600 mg abacavir, and 300 mg lamivudine.
Triumeq alone is not recommended for people with known HIV resistance to abacavir, lamivudine or any of the approved integrase inhibitors.
Pediatric Dose: N/A
Dosing Info: This is a complete one-pill, once-daily drug regimen. Take with or without food. Contains abacavir and should only be used by patients who have tested negative for HLA-B*5701 (see below).
Common side effects among people using Triumeq including trouble sleeping, headache, tiredness.
Regimens containing abacavir can cause serious and potentially life-threatening allergic (hypersensitivity) reactions. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701. Your healthcare provider can determine with a blood test if you have this gene variation. Symptoms of hypersensitivity reaction may include fever, rash, nausea, vomiting, diarrhea, abdominal pain, malaise, fatigue, or respiratory symptoms such as sore throat, cough, or shortness of breath.
Some studies suggest that current or recent use of regimens containing abacavir can increase the risk of a heart attack. However, this risk has not been confirmed by other studies.
Dolutegravir has been linked to a small risk of neural tube birth defects in infants born to mother who took the medication during early pregnancy. The Food and Drug Administration recommends that women avoid dolutegravir around the time of conception through the first trimester of pregnancy.
Triumeq should not be used at the same time as Tikosyn (dofetilide), a medication used to maintain a normal heart rhythm. The Tivicay in Triumeq can increase Tikosyn blood levels, which can lead to life-threatening problems.
One additional 50mg tablet of Tivicay (dolutegravir) taken 12 hours apart if Triumeq is taken with Sustiva (efavirenz), boosted-Lexiva (fosamprenavir/ritonavir), boosted-Aptivus (tipranavir/ritonavir), rifampin, or Tegretol (carbamazepine).
With the exception of Tivicay in certain circumstances, Triumeq should not be combined with any HIV medications that contain any of the active ingredients in Triumeq. These include: Epivir, Epzicom, Trizivir, and Ziagen. Combining Triumeq with HIV medications containing active ingredients similar to those in Triumeq should also be avoided. These include: Atripla, Complera, Emtriva, Genvoya, Isentress, Viread, or Vitekta.
Trileptal (oxcarbazepine), phenytoin, phenobarbital, and St. John’s wort can reduce levels of dolutegravir in the blood. These drugs should be avoided while using Triumeq.
Triumeq should be taken two hours before or six hours after taking certain (cation-containing) antacids or laxatives, sucralfate, oral iron supplements, calcium supplements, or buffered medication.
An increased methadone dose may be required in a small number of patients.
Important hepatitis C treatment drug-drug interactions: Triumeq can be combined with Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Olysio/Sovriad (simeprevir), ribavirin, or pegylated interferon alfa. Interactions with Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) have not been fully evaluated.
Other drug interactions are possible. Consult the Triumeq package insert for more details: https://www.gsksource.com/gskprm/htdocs/documents/TRIUMEQ-PI-MG.PDF
Before taking this medication, tell your doctor if you have kidney disease, liver disease, or any previous experience with a regimen containing abacavir. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Last Reviewed: April 19, 2019